Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Raptor Pharmaceutical Corp.

Division of Horizon Pharma PLC
www.raptorpharma.com

Latest From Chart Industries Inc.

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2010

Highlights from the Q1 2010 review of medical device and in vitro diagnostics/research dealmaking: With most of the funding in the form of venture rounds, medical device financing totaled $548 million in the second quarter, a 10% drop from Q1. Device acquisitions picked up, with 18 transactions completed for an aggregate $4.4 billion. Including GenMark's IPO, the first done in the sector since November 2007, in vitro diagnostic/research financing more than doubled Q1's dollar volume, reaching $364 million in the second quarter. The four IVD/Research acquisitions done in Q2 totalled $226 million.
Medical Device

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2009

Medical device financing--primarily made up of late venture rounds--totaled just over $1 billion in Q3 2009, a 19% increase over the previous quarter. Acquisition dollars in the industry also surpassed $1 billion and included two $400 million-deals by Abbott. Most of the third quarter financing into in vitro diagnostics and research/analytical came from Qiagen's $628 million FOPO. And Agilent's $1.5 billion purchase of bioanalytical instrument maker Varian was the highest-value takeover.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Raptor Pharmaceutical Inc.
  • Raptor Pharmaceuticals Corp.
  • TorreyPines Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Horizon Pharma PLC
  • Senior Management
  • Julie Anne Smith, Pres. & CEO
    Michael P Smith, CFO
    Todd C Zankel, PhD, CSO
    David A Happel, Chief Commercial Officer
    Kimberly Lee, DO, VP, Corp. Strategy & Communications
    Krisha R Polu, MD, CMO
    Joel M Rothman, VP, Dev. Operations
  • Contact Info
  • Raptor Pharmaceutical Corp.
    Phone: (415) 408-6200
    7 Hamilton Landing
    Ste. 100
    Novato, CA 94949
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register